

1 ***Supplementary Information***

2 **Predicting dissolution and transformation of inhaled nanoparticles in the lung using abiotic**  
3 **flow cells: The case of barium sulfate**

4 Johannes G. Keller<sup>1†</sup>, Uschi Graham<sup>2†</sup>, Johanna Koltermann-Jüly<sup>1</sup>, Robert Gelein<sup>3</sup>, Lan Ma-Hock<sup>1</sup>,  
5 Robert Landsiedel<sup>1</sup>, Martin Wiemann<sup>3</sup>, Günter Oberdörster<sup>3</sup>, Alison Elder<sup>3\*</sup>, Wendel Wohlleben<sup>1\*</sup>

6 Affiliations:

7 † equal contribution

8 \* Correspondence: [alison\\_elder@urmc.rochester.edu](mailto:alison_elder@urmc.rochester.edu); [wendel.wohlleben@basf.com](mailto:wendel.wohlleben@basf.com)

9 <sup>1</sup> BASF SE, Dept. Experimental Toxicology and Ecology, and Dept. Material Physics, 67056  
10 Ludwigshafen, Germany; [johanna.koltermann-juelly@basf.com](mailto:johanna.koltermann-juelly@basf.com), [johannes-georg.keller@basf.com](mailto:johannes-georg.keller@basf.com),  
11 [lan.ma-hock@basf.com](mailto:lan.ma-hock@basf.com), [robert.landsiedel@basf.com](mailto:robert.landsiedel@basf.com), [wendel.wohlleben@basf.com](mailto:wendel.wohlleben@basf.com)

12 <sup>2</sup> National Institute of Occupational Safety and Health, Cincinnati, Ohio, 45226, USA;  
13 [graham@topasol.com](mailto:graham@topasol.com)

14 <sup>3</sup> Biopharmaceutics and Pharmaceutical Technology, Saarland University, 66123 Saarbrücken,  
15 Germany

16 <sup>4</sup> IBE R&D Institute for Lung Health gGmbH, Mendelstr. 11, 48149 Münster, Germany;  
17 [martin.wiemann@ibe-ms.de](mailto:martin.wiemann@ibe-ms.de)

18 <sup>5</sup> University of Rochester Medical Center, Rochester, New York, USA;  
19 [alison\\_elder@urmc.rochester.edu](mailto:alison_elder@urmc.rochester.edu), [gunter\\_oberdorster@urmc.rochester.edu](mailto:gunter_oberdorster@urmc.rochester.edu)

20

21

## 22 Detailed Methods: composition of the buffers

23 We employed two different media with pH 4.5, both simulating the phagolysosomal interior and the  
24 hereby associated processing of phagocytosed particulate matter by alveolar macrophages.[1, 2]

25 The composition of Phagolysosomal simulant fluid (PSF) is:[3] sodium phosphate dibasic anhydrous  
26 ( $\text{Na}_2\text{HPO}_4$ ) 142 mg/L; sodium chloride (NaCl) 6650 mg/L; sodium sulfate anhydrous ( $\text{Na}_2\text{SO}_4$ ) 71 mg/L;  
27 calcium chloride dihydrate ( $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ ) 29 mg/L; glycine ( $\text{C}_2\text{H}_5\text{NO}_2$ ) 450 mg/L (as representative of  
28 organic acids); potassium hydrogen phthalate ( $1-(\text{HO}_2\text{C})-2-(\text{CO}_2\text{K})-\text{C}_6\text{H}_4$ ) 4085 mg/L;  
29 alkylbenzyltrimethylammonium chloride (ABDC) 50 ppm (added as an antifungal agent). The pH was  
30 adjusted to 4.55 using 1 M NaOH (Bernd Kraft). The composition of EU pH4.5 in comparison contains  
31 a richer mix of organic acids and different biocides. However, pH was checked to be stable in eluates  
32 of both simulants.

33

34 **Table S1:** Composition of lysosomal simulant fluids (in mg/L)

Substance	PSF pH4.5	EU pH4.5
NaCl	6650	7120
$\text{Na}_2\text{HPO}_4$	142	148
$\text{Na}_2\text{SO}_4$	71	79
$\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$	29	29
$\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$		211
KH-Phthalate	4085	0
$\text{Na}_3\text{Citrate} \cdot 2\text{H}_2\text{O}$		153
$\text{Na}_2\text{Tartrate} \cdot 2\text{H}_2\text{O}$		180
90% lactic acid		235
NaPyruvate		201
Glycine	450	118
$\text{HCO}_3^-$		1416
alkylbenzyltrimethylammonium chloride (ABDC)	50	
$\text{H}_2\text{CO}$ (Formaldehyde)		799
$\text{CH}_3\text{OH}$		270

36

37

**38 Detailed Methods: Solubility in phagolysosomal simulant fluid under static conditions**

39 Nano-scaled BaSO<sub>4</sub> (NM-220) was suspended either in 200 mL ultrapure water or in 200 mL  
40 phagolysosomal simulant fluid (PSF) at a concentration of 10 mg/mL. The BaSO<sub>4</sub> suspensions were  
41 incubated for 7 or 28 days at 37 °C under continuous stirring (300 rpm). In a second series of  
42 experiments EDTA-Na<sub>2</sub> (Sigma Aldrich, 20 mg/mL) was added to the BaSO<sub>4</sub>-PSF-suspension. EDTA  
43 mimicked alkaline earth metal-transporting proteins. Subsequent to the incubation period, the  
44 remaining particulate matter was separated from the ion solution using ultracentrifugation at  
45 67,000 ×g for 2 h (Beckman L8-70M ultracentrifuge). From preliminary work, it is known that this  
46 material, with its given density, is completely removed from the supernatant at these conditions. The  
47 Ba concentration in the supernatants was analyzed by inductively coupled plasma mass spectrometry  
48 (ICP-MS). The limit of detection was 0.1 ppm, corresponding to 0.001 % dissolution.

49


**50 Detailed Methods: Solubility under quasi-dynamic conditions**

51 BaSO<sub>4</sub> nanoparticles suspended in PSF (10 mg/mL) were injected into a dialysis cassette (Thermo  
52 Scientific). This device was composed of a sealed sample chamber (sample volume 2 mL) enclosed at  
53 two sites by dialysis membranes (7 kDa cutoff). The dialysis cassette, harboring the BaSO<sub>4</sub> suspension,  
54 was placed horizontally (to minimize pelleting) into a glass vessel filled with 200 mL receptor medium  
55 (also PSF). This system was kept at 37 °C for 7 days under continuous stirring of the receptor medium  
56 (300 rpm). During this incubation time the receptor medium was exchanged completely every 24 h on  
57 working days. To minimize evaporation, the glass vessel was closed with parafilm. The ionic Ba content  
58 of each receptor medium sample was quantified by ICP-MS.

59


60 **Additional results**

61



62


63 **Figure S1** Time dependent dissolution of  $\text{BaSO}_4$  in pH neutral medium compared to EU pH4.5 in the  
64 flow-by system. Orange at pH 7.4 and gray at pH 4.5 (37 °C; starting mass, 1.05 mg for PSF, 0.79 mg  
65 for EU pH4.5).



66


67 **Figure S2** Dissolution of 10 mg  $\text{BaSO}_4$  NM-220 in PSF measured in flow-through system (blue) and EU  
68 pH4.5 in the flow-by system (orange).

69



70 **Figure S3** Time dependent dissolution of BaSO<sub>4</sub> in deionized water pH 7.0 compared to PSF pH 4.5 in  
 71 the flow-through system. Blue deionized water at pH 7.0 and yellow PSF at pH 4.5


72



73 **Figure S4** XPS elemental composition (in atom-%) of the residual particles after flow-through testing  
 74 at V=2 mL/h in pH 4.5 PSF for 72 h. For statistical evidence the results from five measurement spots  
 75 were measured and compared.

BaSO<sub>4</sub> original

...after 2h immersion of the TEM grid in PSF



76 **Figure S5** In situ tracking of BaSO<sub>4</sub> morphological changes: particles were wetted by ethanol, then  
 77 immediately dip-coated onto a TEM grid with position markers. The grid was transferred to vacuum  
 78 and a scan of the ‘original’ material was acquired. The grid was recovered from vacuum and immersed  
 79 in PSF pH 4.5 for 2 h, rinsed with water, and a scan at the same position was repeated. This procedure  
 80 does not remove ions by enforced flow but operates at total solids of less than ng/L, hence far below  
 81 the equilibrium. The repeat scan shows that the sphericity of the remaining structures increases at the  
 82 expense of structures with smaller radius of curvature. It appears that ‘sphericity’ is not seen *in vivo*,  
 83 where more crystalline phases with flat surfaces are present with Ostwald ripening.

84

#### 85 **References in SI:**

- 86 1. Nti: PD ISO/TR 19057:2017 - Nanotechnologies. Use and application of acellular in vitro tests  
 87 and methodologies to assess nanomaterial biodurability. In: *Nanotechnologies Use and*  
 88 *application of acellular in vitro tests and methodologies to assess nanomaterial*  
 89 *biodurability*2017.
- 90 2. Oberdörster G, Kuhlbusch TAJ. In vivo effects: Methodologies and biokinetics of inhaled  
 91 nanomaterials. *NanoImpact*. 2018;10 Supplement C:38-60; doi:  
 92 <https://doi.org/10.1016/j.impact.2017.10.007>.  
 93 <http://www.sciencedirect.com/science/article/pii/S2452074817300629>.
- 94 3. Stefaniak AB, Guilmette RA, Day GA, Hoover MD, Breyse PN, Scripsick RC. Characterization of  
 95 phagolysosomal simulant fluid for study of beryllium aerosol particle dissolution. *Toxicology in*  
 96 *Vitro*. 2005;19 1:123-34; doi: 10.1016/j.tiv.2004.08.001.  
 97 <http://www.sciencedirect.com/science/article/pii/S0887233304001250>.